COX-2 Inhibitors and Colon Cancer Risk
Author Information
Author(s): Harris Randall E, Beebe-Donk Joanne, Alshafie Galal A
Primary Institution: The Ohio State University College of Medicine and Public Health
Hypothesis
Do selective and non-selective COX-2 inhibitors reduce the risk of colon cancer?
Conclusion
Both selective and non-selective COX-2 inhibitors significantly reduce the risk of colon cancer.
Supporting Evidence
- Regular intake of NSAIDs reduces colon cancer risk by about 60%.
- Selective COX-2 inhibitors showed a 69% reduction in colon cancer risk.
- Acetaminophen had no significant effect on colon cancer risk.
Takeaway
Taking certain pain relievers called COX-2 inhibitors can help lower the chances of getting colon cancer.
Methodology
A case-control study comparing 326 colon cancer patients with 652 matched controls, assessing medication use and risk factors.
Potential Biases
Potential recall bias in self-reported medication use.
Limitations
The study is observational and may not account for all confounding factors.
Participant Demographics
326 colon cancer patients and 652 controls matched by age, race, and county.
Statistical Information
P-Value
0.01
Confidence Interval
95% CI = 0.16–0.57
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website